PSMD1 and COVID-19: Utilizing modified human screening COVID-19 serological tests (anti-S1 RBD IgG ELISA) for SARS-CoV-2 infection surveillance in the cat population presents potential benefits, although the confirmed seropositivity rate via cPassTM declined to 3.99% while that of the screening test (ELISA) was 22.67%.